MOGAM Institute for Biomedical Research

What MOGAM Institute for Biomedical Research does

MOGAM Institute for Biomedical Research (목암생명과학연구소), founded in 1984 and headquartered in Seoul's Seocho district, is a private South Korean biomedical research organization that has repositioned itself around AI-driven drug discovery. The institute employs 51-100 staff and operates a proprietary AI New Drug Development Platform that performs drug candidate identification, large-scale biomedical data analysis, and clinical trial optimization. A second specialized offering — an AI-based RNA Design and Optimization Technology developed jointly with ST Pharm — targets next-generation RNA therapeutics. The technology stack centers on optimization, predictive analytics, generative AI, and process automation applied to structured biomedical data and scientific text.

MOGAM operates primarily as a government-funded research institute rather than a commercial product vendor. Its revenue mechanics rely on national AI-driven research grants — most notably through Korea's K-Moonshot program led by the Ministry of Science and ICT — supplemented by joint R&D agreements with pharmaceutical and clinical partners. Rather than selling a licensed SaaS product or charging per-seat pricing, the institute captures value through collaborative R&D contracts, licensing/royalty arrangements tied to partnered platforms, and the credibility conferred by selection into flagship national programs. Its primary customer segment is the pharmaceutical industry, served via custom AI tooling and co-development arrangements.

During the first half of 2026, MOGAM signed MOUs or joint R&D agreements with the Ministry of Science and ICT (K-Moonshot, March 2026), Ajou University Medical Center and Quattro Precision Medicine Research Center (precision-medicine drug development, April 2026), and ST Pharm (AI-based RNA design, June 2026). These moves, alongside participation in the New Drug Development AI Platform construction project (May 2026) and the institute's 42nd anniversary in May 2026, indicate an active repositioning from a long-established biomedical research body into a national AI-for-drug-discovery hub. Geographic footprint remains Korea-focused, and there is no evidence of international expansion, equity funding rounds, or commercial product revenue.

Name

MOGAM Institute for Biomedical Research

Legal name

MOGAM Institute for Biomedical Research

Website

https://mogam.re.kr

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

51–100 employees

Short description

MOGAM Institute for Biomedical Research is a Seoul-based private biomedical research institute, founded in 1984, that develops AI-driven drug discovery platforms and AI-based RNA design technology for pharmaceutical companies and Korea's national K-Moonshot research program.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

• AI drug discovery
• Biomedical research
• New drug development
• RNA design technology
• Clinical trial optimization

Headquarters

HQ city

Yongin

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Government-funded Research: As a research institute, MOGAM operates primarily through government-funded research projects and national AI-driven research programs such as K-Moonshot, rather than commercial product revenue

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

MOGAM Institute for Biomedical Research operates an AI-driven drug discovery platform that accelerates new drug development through drug candidate identification, biomedical data analysis, and clinical trial optimization. The institute also develops specialized AI-based RNA design and optimization technology in collaboration with pharmaceutical partners to advance next-generation RNA therapeutics.

Product overview

MOGAM Institute for Biomedical Research operates as a unified AI-driven drug discovery research organization, consisting of a core AI New Drug Development Platform that enables end-to-end drug candidate identification, data analysis, and clinical trial optimization, complemented by specialized AI-based RNA Design and Optimization Technology developed through strategic partnerships. The institute leverages its AI capabilities as the foundational technology across all research activities, positioning its AI platform as the central enabler for all drug development processes.

Differentiator

Problem solved

Functional benefit

Products and services

• AI New Drug Development Platform (AI 기반 신약개발 플랫폼)
• AI-based RNA Design and Optimization Technology (AI 기반 RNA 설계·최적화 기술)

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• ST PharmcoreStrategic or Co-development Partner · 18 June 2026MOGAM Institute signed a joint R&D agreement with ST Pharm (CEO Sung Mu-je) to develop AI-based RNA design and optimization technology. The partnership combines MOGAM's AI platform capabilities with ST Pharm's RNA technology expertise to advance next-generation RNA design techniques.
• Ajou University Medical Center and Quattro Precision Medicine Research CentercoreStrategic or Co-development Partner · 22 April 2026MOGAM Institute signed an MOU with Ajou University Medical Center and Quattro Precision Medicine Research Center for AI-based new drug development research. This trilateral partnership aims to advance precision medicine through collaborative research combining clinical expertise with AI-driven drug discovery capabilities.
• Ministry of Science and ICTflagshipStrategic or Co-development Partner · 18 March 2026MOGAM Institute signed an MOU with Korea's Ministry of Science and ICT on March 11, 2026, formalizing its selection as a partner institution for the K-Moonshot national AI-driven research program. The institute participates in the Advanced Biotechnology and New Drug Development sector, contributing AI capabilities to accelerate drug candidate identification, data analysis, and clinical trial optimization.

Scale indicators2 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Atomwise: Atomwise builds AtomNet, an AI platform for structure-based small-molecule discovery, partnering with pharma and academic groups. Comparable to MOGAM as an AI drug discovery platform serving pharmaceutical discovery needs through research collaborations.
• BenevolentAI: BenevolentAI applies machine learning to drug discovery and development, with a focus on target identification and clinical decision support. Comparable to MOGAM's stated capabilities in drug candidate identification and clinical trial optimization via AI.
• XtalPi: XtalPi combines AI, quantum physics, and robotics to accelerate drug discovery and has partnered with major Asian and global pharma. Comparable to MOGAM in offering AI-enabled candidate design and serving Asian pharmaceutical partners, with strong regional overlap in Korea and China.
• Exscientia: Exscientia is an AI-native pharma using its platform to design novel drug candidates and advance them to the clinic. Directly comparable to MOGAM's core activity of AI-driven candidate identification, with a similar partner-oriented GTM motion toward global pharma.
• Insilico Medicine: Insilico Medicine is a clinical-stage AI drug discovery company applying end-to-end ML platforms (PandaOmics, Chemistry42, InClinico) to identify novel targets, design molecules, and predict clinical trial outcomes. Directly comparable to MOGAM in applying generative AI across target ID, candidate optimization, and clinical-trial analytics.
• Recursion Pharmaceuticals: Recursion combines high-throughput wet-lab experimentation with AI/ML models to discover and develop novel therapeutics at scale. Comparable to MOGAM as an AI-driven drug discovery organization, though at much larger scale and with a publicly traded platform spanning multiple therapeutic areas.
• Schrödinger: Schrödinger provides physics-based computational platforms and AI/ML tools for molecular design, used by pharma and biotech globally. Comparable to MOGAM in delivering AI-enabled drug candidate identification and optimization via a software-and-services model to pharmaceutical partners.

Emerging players

• Biorelate: Biorelate applies AI to biomedical knowledge extraction and target discovery, an emerging player adjacent to MOGAM's early-stage candidate identification work. Comparable as an emerging AI-for-biomedical-research platform but narrower in scope than MOGAM's full discovery stack.

Broad incumbents

• Isomorphic Labs: Isomorphic Labs, Alphabet's drug discovery subsidiary, applies AlphaFold-derived AI to pharmaceutical R&D at global-enterprise scale. A broad incumbent in AI drug discovery — overlaps with MOGAM's mission but operates with substantially larger capital, data, and partner footprint.

Others

• ST Pharm: ST Pharm is a Korean oligonucleotide API and CDMO partner of MOGAM (joint R&D June 2026). Listed here as an ecosystem partner rather than a competitor — ST Pharm provides RNA manufacturing capability that complements MOGAM's AI-driven RNA design and optimization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/mogam

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MOGAM Institute for Biomedical Research